Ftse Mib
34.127,62
-0,72%
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
NASDAQ
19.621,68
1,77%
Bitcoin
98.154,25
-0,16%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Cellectis Nom Eo 05 (ALCLS) Cellectis Nom Eo 05 (ALCLS) Notizie

Cellectis Nom Eo 05

ALCLS
1,654
-0,066 (-3,84%)
03 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: Euronext
Tipo: Azione Ordinaria
Valuta: EUR

Ultime notizie

Data Ora Fonte Titolo
10/12/202422:30UKREGCellectis annonce le tirage de la troisième tranche de 5..
10/12/202422:30UKREGCellectis announces the drawdown of the third tranche of €5..
10/12/202422:30GLOBECellectis announces the drawdown of the third tranche of €5..
04/12/202422:30UKREGMonthly information on share capital and company voting..
04/12/202422:30UKREGInformation mensuelle relative au nombre total des droits de..
06/11/202422:38UKREGMonthly information on share capital and company voting..
06/11/202422:38UKREGInformation mensuelle relative au nombre total des droits de..
05/11/202422:30GLOBECellectis Presents Multiple Strategies to Enhance CAR T-cell..
05/11/202422:30UKREGCellectis Presents Multiple Strategies to Enhance CAR T-cell..
05/11/202422:30UKREGCellectis présente de multiples stratégies pour améliorer..
04/11/202422:30UKREGCellectis Provides Business Updates and Financial Results..
04/11/202422:30GLOBECellectis Provides Business Updates and Financial Results..
04/11/202422:30UKREGCellectis présente ses résultats financiers du troisième..
30/10/202421:30UKREGCellectis to Report Third Quarter 2024 Financial Results on..
30/10/202421:30UKREGCellectis publiera ses résultats financiers du troisième..
30/10/202421:30GLOBECellectis to Report Third Quarter 2024 Financial Results on..
22/10/202408:00UKREGCellectis to Present Data on TALE-Base Editors and Non-Viral..
22/10/202408:00UKREGCellectis présentera des données sur des TALE Base..
22/10/202408:00GLOBECellectis to Present Data on TALE-Base Editors and Non-Viral..
02/10/202422:30UKREGMonthly information on share capital and company voting..
02/10/202422:30UKREGInformation mensuelle relative au nombre total des droits de..
04/9/202422:30UKREGMonthly information on share capital and company voting..
04/9/202422:30UKREGInformation mensuelle relative au nombre total des droits de..
03/9/202422:30GLOBECellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells..
03/9/202422:30UKREGCellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells..
03/9/202422:30UKREGCellectis présente des preuves précliniques de l’efficacité..
26/8/202422:30GLOBECellectis Publishes a Molecular Therapy Article on a SMART..
26/8/202422:30UKREGCellectis publie un article dans Molecular Therapy sur la..
26/8/202422:30UKREGCellectis Publishes a Molecular Therapy Article on a SMART..
07/8/202408:00UKREGCellectis Appoints Dr. Adrian Kilcoyne as Chief Medical..
07/8/202408:00GLOBECellectis Appoints Dr. Adrian Kilcoyne as Chief Medical..
07/8/202408:00UKREGCellectis nomme le docteur Adrian Kilcoyne directeur médical
06/8/202422:30UKREGCellectis Provides Financial Results for the Second Quarter..
06/8/202422:30UKREGCellectis publie ses résultats financiers du deuxième..
06/8/202422:30GLOBECellectis Provides Financial Results for the Second Quarter..
05/8/202422:30UKREGMonthly information on share capital and company voting..
05/8/202422:30UKREGInformation mensuelle relative au nombre total des droits de..
01/8/202422:30UKREGLa FDA accorde le statut de médicament orphelin à CLLS52..
01/8/202422:30UKREGFDA Grants Orphan Drug Designation to Cellectis’ CLLS52..
01/8/202422:30GLOBEFDA Grants Orphan Drug Designation to Cellectis’ CLLS52..
25/7/202422:30GLOBEFDA Grants Orphan Drug and Rare Pediatric Disease..
25/7/202422:30UKREGLa FDA accorde le statut de médicament orphelin et..
25/7/202422:30UKREGFDA Grants Orphan Drug and Rare Pediatric Disease..
05/7/202422:30GLOBEMonthly information on share capital and company voting..
05/7/202422:30GLOBEInformation mensuelle relative au nombre total des droits de..
28/6/202422:30GLOBERésultats de l’Assemblée Générale Mixte de Cellectis du 28..
20/6/202422:30GLOBECellectis publie un article scientifique dévoilant trois..
12/6/202422:30GLOBECellectis dévoile une approche de thérapie génique..
05/6/202422:30GLOBEMonthly information on share capital and company voting..
05/6/202422:30GLOBEInformation mensuelle relative au nombre total des droits de..
Apertura: 1,728 Min: 1,652 Max: 1,728
Chiusura: 1,72

La tua Cronologia

EU
ALCLS
Cellectis Nom Eo 05
BIT
P1TPD3
BNP Paribas Issuance
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network